This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 26, 2014 /PRNewswire/ -- Vermillion, Inc. (NASDAQ:
VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on
Thursday, March 6, 2014, at
4:30 p.m. Eastern time to discuss results for the fourth quarter and year ended
December 31, 2013. Financial results will be issued in a press release prior to the call.
Vermillion's President and CEO
Thomas McLain will host the call, followed by a question and answer period.
Thursday, March 6, 2014Time:
4:30 p.m. Eastern time (
3:30 p.m. Central time)Dial-in number: 1-800-763-6049International dial-in number: 1-212-231-2932Conference ID: 21709303Webcast:
The conference call will be webcast live and available for replay via the investor section of the company's website at
Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A replay of the call will be available approximately two hours after the call until
March 20, 2014.
Toll-free replay number: 1-800-633-8284International replay number: 1-402-977-9140 Replay ID: 21709303
About VermillionVermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.
The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit
Investor Relations Contact:Liolios Group, Inc.
Ron Both Tel 1-949-574-3860
SOURCE Vermillion, Inc.